Drug intelligence / Profile preview

Lyzme5

Development stage: Discontinued
Lead developer: All American Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Lyzme5 is a proprietary over-the-counter (OTC) nutritional supplement designed to support weight management and healthy cholesterol levels. It is formulated with a combination of B vitamins and a non-essential amino acid, all of which are classified as Generally Recognized as Safe (GRAS) under the Dietary Supplement Health and Education Act (DSHEA). The supplement was evaluated in an observational clinical study (NCT01634646) to determine its impact on body weight and lipid profiles, including total cholesterol, LDL, and triglycerides, in overweight individuals. The study was sponsored by Lyzme5, LLC, but was ultimately terminated.

Brand names: Lyzme5Lyzme-5Lyzme 5
Other names: Lyzme5Lyzme-5Lyzme 5

Beyond the preview

Go deeper on Lyzme5.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lyzme5.

Explore the full profile